Soluble receptor for advanced glycation end products in late onset neonatal infection

OBJECTIVES: To assess the plasma levels of sRAGE (soluble receptor for advanced glycation end products) in infected and non-infected preterm neonates and to compare their diagnostic values with standard infection biomarkers. BACKGROUND: RAGE activates pathways responsible for acute and chronic inflammation. The soluble type of this receptor, sRAGE, which acts as a decoy receptor, has been linked to the severity of sepsis and its outcome. METHODS: Prospective clinical study was carried out from January 2011 to August 2013. There were 33 neonates included according to their infection status and divided into subgroups as follows: infected (I), septic (S), non-infected controls (C). RESULTS: We found significantly lower values of sRAGE in the subgroup S (905.54+/-220.53 pg/mL; p < 0.028), while borderline values were higher in the subgroup I vs C (2158.33+/-197.33 pg/mL vs 1744.80+/-157.74 pg/mL; p < 0.064). By analysing the interobserver concordance we detected 70 % agreement as to sRAGE values detected in neonatal late-onset infections and sepsis, while procalcitonin was used as golden standard. CONCLUSION: Plasma sRAGE values reflect the severity of the inflammatory status in late-onset infection and sepsis in preterm neonates. Our results indicate that sRAGE could be a good potential biomarker of late-onset neonatal infection and sepsis (Tab. 2, Ref. 14). Text in PDF www.elis.sk.